References
- Huerta S , ChilkaS, BonavidaB. Nitric oxide donors: novel cancer therapeutics (review). Int. J. Oncol.33, 909–927 (2008).
- Stuehr DJ , MarlettaMA. Mammalian nitrate bio-synthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc. Natl Acad. Sci. USA82, 7738–7742 (1985).
- Hibbs JB Jr , TaintorRR, VavrinZ. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science235, 473–476 (1987).
- Burke AJ , SullivanFJ, GilesFJ, GlynnSA. The yin and yang of nitric oxide in cancer progression. Carcinogenesis34, 503–512 (2013).
- Ridnour LA , ThomasDD, SwitzerC, WinkDAet al. Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide19, 73–76 (2008).
- Lechner M , LirkP, RiederJ. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin. Cancer Biol.15, 277–289 (2005).
- Li J , BilliarTR, TalanianRV, KimYM. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. Biochem. Biophys. Res Commun.240, 419–424 (1997).
- Kawasaki K , SmithRSJr, HsiehCM, SunJ, ChaoJ, LiaoJK. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol. Cell Biol.235726–5737 (2003).
- Laval F , WinkDA, LavalJA. discussion of mechanisms of NO genotoxicity: implication of inhibition of DNA repair proteins. Rev. Physiol. Biochem. Pharmacol.131, 175–191 (1997).
- Moncada S , HiggsA. The L-arginine-nitric oxide pathway. N. Engl. J. Med.3292002–1993 (2012).
- Rigas B , KashfiK. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol. Med.10, 324–330 (2004).
- Frederiksen LJ , SullivanR, MaxwellLRet al. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin. Cancer Res.13, 2199–2206 (2007).
- Yasuda H , YamayaM, NakayamaKet al. Randomized Phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J. Clin. Oncol.24, 688–694 (2006).
- Sogawa K , Numayama-TsurutaK, EmaM, AbeM, AbeH, Fujii-KuriyamaY. Inhibition of hypoxia-inducible factor 1 activity by nitric oxide donors in hypoxia. Proc. Natl Acad. Sci. USA95, 7368–7373 (1998).
- Keefer LK , NimsRW, DaviesKM, WinkDA. “NONOates” (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods Enzymol.268, 281–293 (1996).
- Huerta S , Baay-GuzmanG, Gonzalez-BonillaCR, LivingstonEH, Huerta-YepezS, BonavidaB. In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: involvement of AIF. Nitric Oxide20, 182–194 (2009).
- Gao X , SahaD, KapurP, AnthonyT, LivingstonEH, HuertaS. Radiosensitization of HT-29 cells and xenografts by the nitric oxide donor DETA-NONOate. J. Surg. Oncol.100, 149–158 (2009).
- Maciag AE , SaavedraJE, ChakrapaniH. The nitric oxide prodrug JS-K and its structural analogues as cancer therapeutic agents. Anticancer Agents Med. Chem.9, 798–803 (2009).
- Yeh RK , ChenJ, WilliamsJLet al. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem. Pharmacol. 67, 2197–2205 (2004).
- Hundley TR , RigasB. Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation. J. Pharmacol. Exp. Ther.316, 25–34 (2006).
- Bratasz A , WeirNM, ParinandiNLet al. Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro de-rivative of aspirin. Proc. Natl Acad. Sci. USA103, 3914–3919 (2006).